Transcatheter closure of patent foramen ovale, atrial septal defect and left atrial appendage

Minerva Cardioangiologica

Volumn 57, Issue 1, 2009, Pages 103-115

  Majunke, N ^a   Wallenborn, J ^a   Wunderlich, N ^a   Sievert, H ^a,b  

^a CARDIOVASCULAR CENTER FRANKFURT   (Germany)

^b WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Congenital foramen ovale; Heart defects; Patent stroke

Indexed keywords

ACETYLSALICYLIC ACID; PHENPROCOUMON;

CLINICAL TRIAL; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART ATRIUM SEPTUM DEFECT; HEART CATHETERIZATION; HEART LEFT ATRIUM; HEART LEFT ATRIUM APPENDAGE; HUMAN; MIGRAINE; PATENT FORAMEN OVALE; REVIEW; STROKE; BALLOON OCCLUSION; EVIDENCE BASED MEDICINE; HEART ATRIUM APPENDAGE; HEART SEPTUM DEFECT; IMPLANTATION; PROSTHESIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ATRIAL APPENDAGE; BALLOON OCCLUSION; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; FORAMEN OVALE, PATENT; HEART SEPTAL DEFECTS, ATRIAL; HUMANS; PROSTHESIS DESIGN; PROSTHESIS IMPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TREATMENT OUTCOME;

EID: 67849110071     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac M et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988;318:1148-52.
2. Cujec B, Mainra R, Johnson DH. Prevention of recurrent cerebral ischemic events in patients with patent foramen ovale and cryptogenic strokes or transient ischemic attacks. Can J Cardiol 1999;15:57-64.
3. Knauth M, Ries S, Pohlmann S, Kerby T, Forsting M, Daffertshofer M et al. Cohort study of multiple brain lesions in sport divers: Role of a patent foramen ovale. BMJ 1997;314:701-5.
4. Sztajzel R, Genoud D, Roth S, Mermillod B, Le Floch-Rohr J. Patent foramen ovale, a possible cause of symptomatic migraine: A study of 74 patients with acute ischemic stroke. Cerebrovasc Dis 2002;13:102-6.
5. Di Tullio MR, Sacco RL, Sciacca RR, Jin Z, Homma S. Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. J Am Coll Cardiol 2007;49:797-802.
6. Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac M et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988;318:1148-52.
7. Webster MW, Chancellor AM, Smith HJ, Swift DL, Sharpe DN, Bass NM et al. Patent foramen ovale in young stroke patients. Lancet 1988;2:11-2.
8. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of Medical Treatment in Stroke Patients With Patent Foramen Ovale. Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation 2002;105:2625-31.
9. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a metaanalysis of case-control studies. Neurology 2000;55:1172-9.
10. Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med 2007;357:2262-8.
11. Silver MD, Dorsey JS. Aneurysms of the septum primum in adults. Arch Pathol Lab Med 1978;102:62-5.
12. Agmon Y, Khandheira BK, Meissner I, Gentile F, Whisnant JP, Sicks JD et al. Frequency of atrial septal aneurysms in patients with cerebral ischemic events. Circulation 1999;99:1942-4.
13. Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001;345:1740-6.
14. Schuchlenz HW, Weihs W, Horner S, Quehenberger F. The association between the diameter of a patent foramen ovale and the risk of embolic cerebrovascular events. Am J Med 2000;109:456-62.
15. De Castro S, Cartoni D, Fiorelli M, Rasura M, Anzini A, Zanette EM et al. Morphological and functional characteristics of patent foramen ovale and their embolic implications. Stroke 2000;31:2407-13.
16. Thanopoulos BV, Dardas PD, Karanasios E, Mezilis N. Transcatheter closure versus medical therapy of patent foramen ovale and cryptogenic stroke. Catheter Cardiovasc Interv 2006;68:741-6.
17. Homma S, Sacco RL. Patent foramen ovale and stroke. Circulation 2005;112:1063-72.
18. Windecker S, Wahl A, Nedeltchev K, Arnold M, Schwerzmann M, Seiler C et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J Am Coll Cardiol 2004;44:750-8.
19. Wöhrle J. Closure of patent foramen ovale after cryptogenic stroke. Lancet 2006;368:350-2.
20. Khairy P, O'Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med 2003;139:753-60.
21. Welch KMA. Contemporary concepts of migraine pathogenesis. Neurology 2003;61:S2-S8.
22. Silberstein SD. Migraine. Lancet 2004;363:381-91.
23. Anzola GP, Magoni M, Guindani M, Rozzini L, Dalla Volta G. Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study. Neurology 1999;52:1622-5.
24. Jesurum JT, Fuller CJ, Velez CA, Spencer MP, Krabill KA, Likosky WH et al. Migraineurs with patent foramen ovale have larger right-to-left shunt despite similar atrial septal features. J Headache Pain 2007;8:209-16.
25. Anzola GP, Morandi E, Casilli F, Onorato E. Different degrees of right-to-left shunting predict migraine and stroke: data from 420 patients. Neurology 2006;66:765-7. (Pubitemid 43739842)
26. Jesurum JT, Fuller CJ, Kim CJ, Krabill KA, Spencer MP, Olsen JV et al. Frequency of migraine headache relief following patent foramen ovale "closure" despite residual right-to-left shunt. Am J Cardiol 2008;102:916-20.
27. Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet 2000;356:1648-51.
28. Schwerzmann M, Wiher S, Nedeltchev K, Mattle HP, Wahl A, Seiler C et al. Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks. Neurology 2004;62:1399-401.
29. Post MC, Thijs V, Herroelen L, Budts WI. Closure of a patent foramen ovale is associated with a decrease in prevalence of migraine. Neurology 2004;62:1439-40.
30. Azarbal B, Tobis J, Suh W, Chan V, Dao C, Gaster R. Association of interatrial shunts and migraine headaches Impact of transcatheter closure. J Am Coll Cardiol 2005;45:489-92. (Pubitemid 40222238)
31. Reisman M, Christofferson RD, Jesurum J, Olsen JV, Spencer MP, Krabill KA et al. Migraine headache relief after transcatheter closure of patent foramen ovale. J Am Coll Cardiol 2005;45:493-5.
32. Giardini A, Donti A, Formigari R, Salomone L, Prandstraller D, Bonvicini M et al. Transcatheter patent foramen ovale closure mitigates aura migraine headaches abolishing spontaneous right-to-left shunting. Am Heart J 2006;151:922.e1-922.e5.
33. Anzola G, Frisoni GB, Morandi E, Casilli F, Onorato E. Shuntassociated migraine responds favorably to atrial septal repair: a casecontrol study. Stroke 2006;37:430-4. (Pubitemid 43732000)
34. Dowson A, Mullen MJ, Peatfield R, Muir K, Khan AA, Wells C et al. Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation 2008;117:1397-404.
35. Bridges ND, Hellenbrand W, Latson L, Filiano J, Newburger JW, Lock JE. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation 1992;86:1902-8.
36. Chatterjee T, Petzsch M, Ince H, Rehders TC, Körber T, Weber F et al. Interventional closure with Amplatzer PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism. J Interv Cardiol 2005;18:173-9.
37. Hausdorf G, Kaulitz R, Paul T, Carminati M, Lock J. Transcatheter closure of atrial septal defect with a new flexible, self-centering device (the STARFlex® Occluder). Am J Cardiol 1999;84:1113-6. (Pubitemid 29505392)
38. Fischer D, Fuchs M, Schaefer A, Schieffer B, Jategaonkar S, Hornig B et al. Transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Procedural and follow-up results after implantation of the Starflex occluder device with conjunctive intensified anticoagulation regimen. J Interv Cardiol 2008;21:183-9.
39. Mullen MJ, Hildick-Smith D, De Giovanni JV, Duke C, Hillis WS, Morrison WL et al. BioSTAR Evaluation STudy (BEST): A prospective, multicenter, phase I clinical trial to evaluate the feasibility, efficacy, and safety of the BioSTAR bioabsorbable septal repair implant for the closure of atrial-level shunts. Circulation 2006;114:1962-7. (Pubitemid 44665391)
40. Billinger K, Ostermayer S, Carminati M, DeGiovanni J, Ewert P, Hess J et al. HELEX septal occluder for transcatheter closure of patent foramen ovale: multicentre experience. Eurointervention 2006;1:465-71.
41. Büscheck F, Sievert H, Kleber F, Tiefenbacher C, Krumsdorf U, Windecker S et al. Patent Foramen Ovale Using the Premere Device: The Results of the CLOSEUP Trial. J Interv Cardiol 2006;19:328-33.
42. Ewert P, Söderberg B, Dähnert I, Hess O, Schuler G, Bussmann C et al. ASD and PFO closure with the Solysafe septal occluder - results of a prospective multicenter pilot study. Catheter Cardiovasc Interv 2008;71:398-402. (Pubitemid 351428163)
43. Krizanic F, Sievert H, Pfeiffer D, Konorza T, Ferrari M, Figulla HR. Clinical evaluation of a novel occluder device (Occlutech((R)) for percutaneous transcatheter closure of patent foramen ovale (PFO). Clin Res Cardiol 2008 Aug 11. [Epub ahead of print]
44. Luermans JG, Post MC, Schräder R, Sluysmans T, Vydt T, Vermeersch P et al. Outcome after percutaneous closure of a patent foramen ovale using the Intrasept device: a multi-centre study. Catheter Cardiovasc Interv 2008;71:822-8.
45. Ruiz CE, Kipshidze N, Chiam PT, Gogorishvili I. Feasibility of patent foramen ovale closure with no-device left behind: first-in-man percutaneous suture closure. Catheter Cardiovasc Interv 2008;71:921-6.
46. Sievert H, Fischer E, Heinisch C, Majunke N, Roemer A, Wunderlich N. Transcatheter Closure of Patent Foramen Ovale Without an Implant. Initial Clinical Experience. Circulation 2007;110:1701-6.
47. King TD, Mills NL. Secundum atrial septal defects: non operative closure during cardiac catheterisation. JAMA 1976;235:2506-9.
48. Rashkind W. Transcatheter treatment of congenital heart disease. Circulation 1983;67:711-6.
49. Lock JE, Rome JJ, Davis R, Van Praagh S, Perry SB, Van Praagh R et al. Transcatheter closure of atrial septal defects: experimental studies. Circulation 1989;79:1091-9.
50. Rao PS, Berger F, Rey C, Haddad J, Meier B, Walsh KP et al. Results of trans-venous occlusion of secundum atrial septal defects with the 4th generation buttoned device: comparison with 1st, 2nd, and 3rd generation devices. International Buttoned Device Trial Group. J Am Coll Cardiol 2000;36:583-92.
51. Hausdorf G, Schneider M, Franzbach B, Kampmann C, Kargus K, Goeldner B. Transcatheter closure of secundum atrial septal defects with the atrial septal defect occlusion system: initial experience in children. Heart 1996;75:83-8. (Pubitemid 26058460)
52. Das GS, Voss G, Jarvis G, Wyche K, Gunther R, Wilson RF. Experimental atrial septal defect closure with a new, transcatheter, self-centering device. Circulation 1993;88:1754-64. (Pubitemid 23296922)
53. Sievert H, Babic UU, Hausdorf G, Schneider M, Höpp HW, Pfeiffer D et al. Transcatheter closure of atrial septal defect and patent foramen ovale with the ASDOS device (a multi-institutional European trial). Am J Cardiol 1998;82:1405-13.
54. Nugent AW, Britt A, Gauvreau K, Piercey GE, Lock JE, Jenkins KJ. Device closure rates of simple atrial septal defects optimized by the STARFlex device. J Am Coll Cardiol 2006;48:538-44. (Pubitemid 44093967)
55. Jones TK, Latson LA, Zahn E, Fleishman CE, Jacobson J, Vincent R et al. Results of the U.S. multicenter pivotal study of the HELEX septal occluder for percutaneous closure of secundum atrial septal defects. J Am Coll Cardiol 2007;49:2215-21. (Pubitemid 46830741)
56. Omeish A, Hijazi ZM. Transcatheter closure of atrial septal defects in children and adults using the Amplatzer Septal Occluder. J Interv Cardiol 2001;14:37-44. (Pubitemid 32216232)
57. Halabi A, Hijazi ZM. A new device to close secundum atrial septal defects: first clinical use to close multiple defects in a child. Catheter Cardiovasc Interv 2008;71:853-6. (Pubitemid 351656340)
58. Goy JJ, Stauffer JC, Yusoff Z, Wong AR, Owlya R, Perret F et al. Percutaneous closure of atrial septal defect type ostium secundum using the new Intrasept occluder: initial experience. Catheter Cardiovasc Interv 2006;67:265-7. (Pubitemid 43235161)
59. Sandercock P, Bamford J, Dennis M. Atrial fibrillation and stroke prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire Community Stroke Project). BMJ 1992;305:1460-5.
60. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000;35:183-7.
61. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
62. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996;61:755-9.
63. Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R et al. Lessons from the Stroke Prevention in Atrial Fibrillation Trials. Ann Intern Med 2003;138:831-8. (Pubitemid 38124645)
64. Brass LM, Krumholz HM, Scinto JM, Radford M. Warfarin use among patients with atrial fibrillation. Stroke 1997;28:2382-9. (Pubitemid 28007636)
65. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000;160:41-6.
66. Blackshear JL, Odell JA Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996;61:755-9.
67. Johnson WD, Ganjoo AK, Stone CD, Srivyas RC, Howard M. The left atrial appendage: our most lethal human attachment! surgical implications. Eur J Cardiothorac Surg 2000;17:718-22. (Pubitemid 30364952)
68. Odell JA, Blackshear JL, Davies E, Byrne WJ, Kollmorgen CF et al. Thoracoscopic obliteration of the left atrial appendage: potential for stroke reduction? Ann Thorac Surg 1996;61:565-9.
69. Ostermayer SH, Reisman M, Kramer PH, Matthews RV, Gray WA, Block PC et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol 2005;46:9-14.
70. Sick PB, Schuler G, Hauptmann KE, Grube E, Yakubov S, Turi ZG et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2007;49:1490-5. (Pubitemid 46505070)
71. Meier B, Palacios I, Windecker S, Rotter M, Cao QL, Keane D et al. Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation. Catheter Cardiovasc Interv 2003;60:417-22. (Pubitemid 37356515)
72. Sievert H, Lesh MD, Trepels T, Omran H, Bartorelli A, Delia Bella P et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 2002;105:1887-9. (Pubitemid 34437613)